^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

AMG 794

i
Other names: AMG 794, AMG794, AMG-794
Company:
Amgen
Drug class:
CD3 agonist, CLDN6 inhibitor
Related drugs:
4ms
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov)
P1, N=3, Terminated, Amgen | N=98 --> 3 | Trial completion date: Feb 2028 --> Dec 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2023; Amgen has made the business decision to discontinue development of AMG 794. The safety profile of AMG 794 remains unchanged.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
CLDN6 (Claudin 6)
|
AMG 794
1year
A Phase 1 Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and Other Malignant Solid Tumor Indications (clinicaltrials.gov)
P1, N=98, Recruiting, Amgen | Active, not recruiting --> Recruiting | Trial completion date: Jun 2027 --> Feb 2028 | Trial primary completion date: Dec 2025 --> Apr 2026
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
CLDN6 (Claudin 6)
|
CLDN6 expression
|
AMG 794
over1year
Enrollment closed • Metastases
|
CLDN6 (Claudin 6)
|
CLDN6 expression
|
AMG 794
over1year
Enrollment open • Metastases
|
CLDN6 (Claudin 6)
|
CLDN6 expression
|
AMG 794
almost2years
Trial completion date • Trial primary completion date • Metastases
|
CLDN6 (Claudin 6)
|
CLDN6 expression
|
AMG 794
almost2years
Trial completion date • Trial primary completion date • Metastases
|
CLDN6 (Claudin 6)
|
CLDN6 expression
|
AMG 794
over2years
A Safety, Tolerability, and Pharmacokinetics Study of AMG 794 With Claudin 6-positive Non-squamous Non-small Cell Lung Cancer or Epithelial Ovarian Cancer. (clinicaltrials.gov)
P1, N=98, Not yet recruiting, Amgen | Trial completion date: May 2026 --> Jun 2027 | Initiation date: May 2022 --> Oct 2022 | Trial primary completion date: Jul 2024 --> Dec 2025
Trial completion date • Trial initiation date • Trial primary completion date
|
CLDN6 (Claudin 6)
|
CLDN6 expression
|
AMG 794
over2years
New P1 trial
|
CLDN6 (Claudin 6)
|
CLDN6 expression
|
AMG 794